90%Confidence
0Views
FDASource
2026-05-27Date
Summary
A second Ajanta Pharma recall for nitrosamine impurity in duloxetine 20mg capsules confirms systemic quality issues. This pattern increases likelihood of FDA import bans and long-term revenue erosion.
Actionable: Sell Ajanta Pharma holdings; consider shorting or avoiding stocks with similar impurity risks.
AI Confidence: 90%
Data Points
firmAjanta Pharma Ltd.
classificationClass II
statusOngoing
distributionNationwide within U.S
productDuloxetine Delayed-Release Capsules, 20 mg, Rx Only, 60 capsules, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India, NDC 27241
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now